Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Loa Loa (eye worm) | hypothetical protein | 0.0012 | 0.099 | 0.2336 |
Onchocerca volvulus | 0.0024 | 0.4238 | 0.5 | |
Loa Loa (eye worm) | intermediate filament protein | 0.0024 | 0.4238 | 1 |
Echinococcus multilocularis | lamin dm0 | 0.0024 | 0.4238 | 1 |
Leishmania major | cytochrome p450-like protein | 0.0011 | 0.0824 | 0.5 |
Loa Loa (eye worm) | cytochrome P450 family protein | 0.0011 | 0.0824 | 0.1944 |
Brugia malayi | Intermediate filament tail domain containing protein | 0.0024 | 0.4238 | 1 |
Brugia malayi | cytoplasmic intermediate filament protein | 0.0013 | 0.1323 | 0.1463 |
Loa Loa (eye worm) | cytoplasmic intermediate filament protein | 0.0013 | 0.1323 | 0.3123 |
Onchocerca volvulus | 0.0024 | 0.4238 | 0.5 | |
Loa Loa (eye worm) | intermediate filament tail domain-containing protein | 0.0024 | 0.4238 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0024 | 0.4123 | 0.9729 |
Echinococcus granulosus | lamin dm0 | 0.0024 | 0.4238 | 1 |
Brugia malayi | intermediate filament protein | 0.0024 | 0.4238 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0024 | 0.4238 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0011 | 0.0875 | 0.2065 |
Mycobacterium ulcerans | cytochrome P450 185A4 Cyp185A4 | 0.0011 | 0.0824 | 0.5 |
Echinococcus granulosus | intermediate filament protein | 0.0024 | 0.4238 | 1 |
Loa Loa (eye worm) | CYP4Cod1 | 0.0011 | 0.0824 | 0.1944 |
Echinococcus multilocularis | musashi | 0.0024 | 0.4238 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0011 | 0.0875 | 0.2065 |
Trypanosoma brucei | cytochrome P450, putative | 0.0011 | 0.0824 | 0.5 |
Echinococcus multilocularis | lamin | 0.0024 | 0.4238 | 1 |
Trypanosoma cruzi | cytochrome P450, putative | 0.0011 | 0.0824 | 0.5 |
Trypanosoma cruzi | cytochrome P450, putative | 0.0011 | 0.0824 | 0.5 |
Loa Loa (eye worm) | cytochrome P450 family protein | 0.0011 | 0.0824 | 0.1944 |
Echinococcus granulosus | lamin | 0.0024 | 0.4238 | 1 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.